Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 9, 2002, Pages 1452-1458

  Sukhova, Galina K ^a   Williams, J Koudy ^b   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Inflammation; Macrophages; Serum cholesterol; Statins

Indexed keywords

CHOLESTEROL; COLLAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; PRAVASTATIN; SIMVASTATIN; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY LESION; ARTERY MEDIA; ARTICLE; ATHEROGENIC DIET; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; INFLAMMATION; MACROPHAGE; MALE; MONKEY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, DIETARY; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS; MACACA FASCICULARIS; MALE; MATRIX METALLOPROTEINASES; PRAVASTATIN; SIMVASTATIN; THROMBOPLASTIN; TUNICA INTIMA; TUNICA MEDIA; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION;

EID: 0036736742     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000030360.72503.56     Document Type: Article

References (51)

1. Molecular bases of the acute coronary syndromes
2. Plaque fissuring: The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina
3. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
4. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture
5. Macrophages and atherosclerotic plaque stability
6. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques
7. Tissue factor in the pathogenesis of atherosclerosis
8. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
9. Selective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
11. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
12. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
13. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study
14. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
15. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
16. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
17. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits
18. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization
19. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators
20. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators
21. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
22. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
23. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke
24. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
25. Estrogen modulates responses of atherosclerotic coronary arteries
26. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries
27. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis
28. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections
29. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion
30. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
31. Macrophages, smooth muscle cells, and tissue factor in unstable angina: Implications for cell-mediated thrombogenicity in acute coronary syndromes
32. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
33. Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation: Cholesterol and Recurrent Events
34. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
35. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
36. Modulation of coronary vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
37. Effects of atherosclerosis and regression on vascular responses to products of activated platelets in primates
38. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
39. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes
40. Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
41. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
42. The role of macrophages in atherogenesis
43. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
44. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
45. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions
46. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: A novel collagenolytic pathway suggested by transcriptional profiling
47. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis
48. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
49. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects: In vitro effect of cerivastatin